BMY

Bristol Myers??? Camzyos delivers durable five-year benefits, rising sales and potential adolescent label expansion.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Bristol Myers Squibb remains a Strong Buy, trading at a 51% discount to sector median with a compelling risk/reward profile. BMY's growth portfolio delivered 15% YoY revenue growth, offsetting headwinds from Opdivo's decline and upcoming Eliquis patent expiry. The company boasts a 3.7% forward dividend yield, robust margins, and accelerating bottom-line growth, supporting its defensive, income-generating appeal.

Bristol Myers Squibb remains undervalued, trading at a 9.8x forward P/E with a 3.7% yield. BMY's growth portfolio now drives nearly 60% of revenue, offsetting legacy drug declines and supporting 5% YoY total revenue growth. Management raised full-year adjusted EPS guidance, with robust Eliquis growth and a strong pipeline of over 10 potential new medicines.

Technical indicators have turned bullish for the three stocks.

XLV bundles the entire healthcare sector into one tidy package, but its cap-weighted structure quietly siphons off the income that dividend investors came for. Three stocks already inside the fund tell a very different yield story.

BMY's Camzyos gains momentum as an adolescent expansion nears an FDA decision, while rivals advance competing heart drugs.

PFE and BMY both boast strong oncology portfolios, but Pfizer's valuation and broader diversification make it the more attractive pick now.

Bristol Myers Squibb has ended its partnership with cell therapy startup Cellares to expand the manufacturing of its ​personalized blood cancer therapy, a company spokesperson told ‌Reuters on Tuesday.

BMY's legacy portfolio faces generic pressure, but stronger Eliquis sales prompt a brighter 2026 revenue outlook.